

Guidance on *Mycoplasma genitalium* testing and management in Ireland, January 2021

Introduction and Background

Mycoplasma genitalium is an emerging STI. The pathophysiology is incompletely understood but it has been implicated in urethritis, epididymorchitis and proctitis in males and pelvic inflammatory disease (PID) in females. The prevalence of infection with *Mycoplasma genitalium* (*M gen*) in Ireland is unknown. Antimicrobial resistance is a particular challenge with this organism, highlighting the need for prudent and judicious use of testing and antimicrobial agents.

In response to concerns around the absence of national guidance on testing and management in Ireland and concerns relating to variation in how individuals are being managed a small group developed a short life working groupⁱ tasked with developing evidence informed guidance on testing and management of *M gen* in Ireland. The recently published BASHH guidelines¹ were used with additional local information where available. Prior to publication of this final version on the HSE Sexual Health and Crisis Pregnancy Programme website, this document was subject to review and comment by relevant professional bodies through a consultation process.

M gen is not currently a notifiable infection. Given the particular challenge relating to antimicrobial resistance with this organism, it is the view of the working group that steps should be taken to making *M gen* a notifiable infection. In that regard the chair of the working group has made representation to the Health Protection Surveillance Centre.

In light of the COVID19 pandemic and the impact it has had on access to STI testing, diagnostics and care some amendments were made to the treatment recommendations in January 2021. The changes are *in italics* below.

Publication Date: January 2020, amended January 2021

Review Date: This guidance will be reviewed 2 years following publication with interim reviews as required in the intervening time period. The SHCPP will ask the working group, via the Chair, Dr. Fiona Lyons, to reconvene when this guidance is due for review.

Recommendations	Comment
1. Who to test?	
All patients presenting with symptoms and signs of PID ²	In line with current BASHH guidelines
All patients presenting with symptoms and signs of urethritis who are CTNG ³ negative and have failed to respond to 1/52 doxycycline	BASHH currently recommends testing of all with symptoms and signs of urethritis, though it is known that <i>M gen</i> testing is not available in many sites. The current recommendation in Ireland will be kept under review.
All patients presenting with sexually acquired epididymorchitis	In line with current BASHH guidelines (consider)
Patients presenting with proctitis where other common causes have been excluded	It is recommended that this is done in the specialist STI setting. Routine rectal testing of patients presenting with proctitis is not currently recommended.
Current sexual partners (regular and non-regular partners where there is likely to be further sexual contact) of those who are <i>M</i>	In line with current BASHH guidelines

¹ BASHH, British Association for Sexual Health and HIV national guideline for the management of infection with *Mycoplasma genitalium* (2018), <https://www.bashhguidelines.org/media/1198/mg-2018.pdf>

² Pelvic Inflammatory disease

³ CTNG, *Chlamydia trachomatis* *Neisseria gonorrhoea*

<i>gen</i> positive. It is reasonable to wait for the result in the contact before treating with clear advice on abstaining from unprotected sexual contact during that time.	
Testing of asymptomatic individuals is not currently recommended (unless they are current sexual contact of a known positive individual)	In line with current BASHH guidelines
2. How and where to test?	
It is recommended that all <i>M gen</i> testing is done using accredited tests.	The NVRL currently uses the Hologic platform.
It is recommended that resistance testing is performed on all positive samples.	The COVID19 pandemic has placed significant challenges on laboratory capacity and diagnostics. As a result, there are delays in the turnaround time for resistance testing and samples are currently being sent to Public Health England. At this time fluoroquinolone resistance testing is NOT available. .
In males with urethritis and/or epididymorchitis, the sample of choice is a first void urine	In line with current BASHH guidelines
In patients with proctitis where <i>M gen</i> infection is considered likely, the sample of choice is a rectal swab	Rectal testing in asymptomatic individuals is not currently recommended .
In females the sample of choice is a vaginal swab (provider or self-taken)	In line with current BASHH guidelines
Pharyngeal testing is not currently recommended	
3. Management of positive results	
<i>Where to see patients?</i>	
It is recommended that all patients testing positive for <i>M gen</i> are referred to an STI clinic for management	
<i>Antibiotic recommendations</i>	
Non-specific urethritis (where CTNG and <i>M gen</i> status are unknown) <ul style="list-style-type: none"> ➤ Doxycycline 100mg BD x 1/52 orally ➤ Where it is not possible to use doxycycline, azithromycin 1g stat orally followed by 500mg orally once daily for 2 days 	Single dose azithromycin for treatment of non-specific urethritis (where CTNG and mycoplasma status are unknown) is NOT recommended.
Positive <i>M gen</i>: resistance unknown or known macrolide resistance <ul style="list-style-type: none"> ➤ Moxifloxacin 400mg orally once daily x 10 days for uncomplicated infection and x 14 days for <i>M gen</i> related PID and epididymorchitis ➤ Where resistance is unknown and there is a contraindication to using moxifloxacin, doxycycline and azithromycin can be considered as outlined below. Positive <i>M gen</i>: isolate known to be macrolide sensitive <ul style="list-style-type: none"> ➤ Doxycycline 100mg twice daily for 7 days followed by azithromycin 1g orally as a single dose then 500mg orally once daily for 2 days ➤ Where it is not possible to use doxycycline, azithromycin 1g stat orally followed by 500mg orally once daily for 2 days 	A recent Irish study from the Gay Men's Health Service in collaboration with the Virology Department at St James's Hospital ⁴ found evidence of macrolide resistance in 75% of isolates. A review of <i>M gen</i> testing over the first year of testing at the NVRL found evidence of macrolide resistance in first presentation samples in 65% and 42% of males and females respectively. ⁵ <u>Use of single dose macrolide monotherapy is NOT recommended.</u>

⁴ Prevalence, Macrolide Resistance, and Fluoroquinolone Resistance in *Mycoplasma genitalium* in Men Who Have Sex With Men Attending an Sexually Transmitted Disease Clinic in Dublin, Ireland in 2017-2018. Mulligan V et al. Sex Transm Dis. 2019 Apr;46(4):e35-e37

⁵ Personal communication Dr. Cillian de Gascun, Director National Virus Reference Laboratory

	Fluoroquinolones are associated with prolonged, disabling and potentially irreversible adverse reactions. This risk is greater in older patients, those with renal impairment and in those on concomitant corticosteroids therapy. The risk of QT prolongation is greater with moxifloxacin than other quinolones. All patients should be assessed for other medication or conditions that may prolong the QT interval. These risks should be discussed with all patients and they should be provided with written information. ⁶
<p>Positive <i>M gen</i>: macrolide and quinolone resistance suspected or known</p> <ul style="list-style-type: none"> ➤ Pristinamycin or Sitofloxacin are treatment options in these circumstances. Doxycycline can reduce bacterial burden in advance of using these medicines which need to be imported. 	Such cases may call for collaboration with international colleagues. Should only be done in a service with experience and expertise in managing <i>M gen</i> resistant cases.
<p>Pregnancy</p> <p>Data on <i>M. gen</i> and its association with adverse pregnancy outcomes are limited, however it has been associated with a small increased risk of preterm delivery and spontaneous abortion.</p> <p>Azithromycin use during pregnancy is unlikely to increase the risk of birth defects or adverse pregnancy outcomes. A three-day course of azithromycin (1g, 500mg, 500mg) can be used for uncomplicated <i>M. gen</i> infection detected in pregnancy where the isolate is known to be macrolide sensitive.</p> <p>The use of moxifloxacin in pregnancy is contra-indicated. In women with likely macrolide resistance, or with upper genital tract infection in pregnancy, options are limited. Although doxycycline is considered safe for use in the first trimester by the FDA, the BNF advises against its use in all trimesters. There are no data regarding the use of pristinamycin in pregnancy. An informed discussion should be had with the pregnant woman around the risks associated with the use of these medicines in pregnancy and the risks of adverse outcomes associated with <i>M. gen</i> infection, and where possible treatment should be delayed until after pregnancy, guided by resistance results.</p>	In line with current BASHH guidelines
<i>Test of Cure</i>	
All patients should attend for a test-of-cure five weeks (and no sooner than three weeks) after the start of treatment to ensure microbiological cure	
<i>Management of contacts</i>	
Current sexual partners (regular and non-regular partners where	

⁶ <http://www.hpra.ie/docs/default-source/publications-forms/newsletters/hpra-drug-safety-newsletter-edition-91.pdf?sfvrsn=7>
Irish Guidance on *Mycoplasma genitalium* testing and management, January 2021

there is likely to be further sexual contact) of those who are <i>M gen</i> positive should be offered testing for <i>M gen</i> .	
Current sexual partners (regular and non-regular partners where there is likely to be further sexual contact) of those who are <i>M gen</i> positive should, where possible, be offered the same treatment as their partner and guided by partner resistance results. It is reasonable to wait for the result (including resistance result) in the contact before treating with clear advice on abstaining from unprotected sexual contact during that time.	
4. Surveillance	
<i>M gen</i> is not currently a notifiable infection. This may change in the future. In the meantime, it is recommended that laboratories and STI services monitor the number of tests, positive results and patient outcomes in line with local audit practices.	

ⁱ Membership of working group

Dr. Fiona Lyons, Chair	St. James's Hospital, Dublin
Dr. Emma Devitt	St. James's Hospital, Dublin
Dr. Brendan Crowley	St. James's Hospital, Dublin
Prof Fiona Mulcahy	St. James's Hospital, Dublin
Dr. Aisling Loy	St. James's Hospital, Dublin
Dr. Almida Lynam	St. James's Hospital, Dublin
Dr. Niamh Lynn	Waterford University Hospital, Dublin
Dr. Eoin Feeney	St. Vincent's University Hospital, Dublin
Dr. Catherine Fleming	University College Hospital, Galway
Dr. Andrea Holmes	University College Hospital, Galway
Dr. Sarah O'Connell	University College Hospital, Limerick
Dr. Cillian DeGascun	National Virus Reference Laboratory